The results emphasize the importance of conserved and cross-reactive responses in vaccine immunogenicity, providing a mechanism through which repeated boosting enhances vaccine immunogenicity in SOTRs and other immunocompromised populations.
Abstract
Introduction Vaccines against SARS-CoV-2 and influenza require reformulation due to viral evolution. It remains unclear how vaccination against evolving antigens influences T-cell responses and the impact of reformulation on T-cell responses to new variants in immunocompromised hosts. Solid organ transplant recipients (SOTRs) had significantly lower antibody levels following vaccination and required repeated boosting during the COVID-19 pandemic. Methods With the introduction of the Omicron spike (S) to the bivalent mRNA vaccines in 2022, the relative contribution of T-cell responses cross-reactive for Omicron mutated S sequences was assessed via intracellular cytokine staining using peptide pools containing conserved or mutated S sequences. Results S-specific CD4 T cells recognize both conserved and Omicron mutated S sequences pre- and post-bivalent vaccination, even in the absence of evidence of prior infection as detected by T-cell responses to a novel peptide pool. CD4 T-cell responses to both conserved and Omicron mutated sequences correlated with antibody pseudo-neutralization of BA.5 S. Importantly, pre-bivalent conserved S CD4 T-cell responses significantly correlated with antibody pseudo-neutralization of BA.5 S post-bivalent. Discussion These results emphasize the importance of conserved and cross-reactive responses in vaccine immunogenicity, providing a mechanism through which repeated boosting enhances vaccine immunogenicity in SOTRs and other immunocompromised populations.
Abstract Objectives Immunocompromised hosts have reduced immune responses to COVID‐19 vaccination, and more severe disease. Antibody responses correlate with protection but markers of immunity vary across a spectrum of immunocompromise. We compared serologic and cellular responses following Ancestral COVID‐19 vaccines...
D. Griffin, P. A. Gill, I. Boo et al.· Clinical & Translational Imm...· 0 citations
SARS-CoV-2 Spike protein evolution compromises sustained efficacy of existing vaccines based on neutralizing antibodies. Here we show that OVX033, a nucleocapsid (NCAP)-based vaccine candidate engineered with the self-assembling oligoDOM™ domain, induces robust cellular immunity in two preclinical models. In hamste...
R. Marlin, C. Primard, Anne-Sophie Gallouët et al.· Communications Biology· 0 citations
OBJECTIVE
To evaluate the durability of SARS-CoV-2-specific humoral and cellular immune responses after booster vaccination in people living with HIV (PLWH) in a prospective longitudinal cohort study.
METHODS
We analyzed 46 PLWH with no prior history of SARS-CoV-2 infection who received a booster dose. Anti-receptor-...
Roser Navarro-Soler, M. J. Heise, T. Dalhuisen et al.· Journal of Acquired Immune D...· 0 citations
Summary Solid organ transplant recipients (SOT) have shown impaired immune responses to infection and vaccination. Here, serological data collected in heart and lung transplant recipients after vaccination against SARS-CoV-2 were analyzed using dimensionality reduction, clustering algorithms and statistical methods to...
Chiara Coppola, Simone Costagli, G. Montesi et al.· iScience· 0 citations
Introduction Understanding how different COVID-19 vaccine combinations shape long-term immunity is essential for improving durability and guiding booster strategies. Despite extensive characterization of neutralizing antibodies, long-term memory B and T cell responses after homologous and heterologous vaccination regim...
N. Che-Kamaruddin, J. Johari, Hasmawati Yahaya et al.· Frontiers in Immunology· 0 citations
Results provide a clear experimental validation proof that microbial epitopes mimicking TAAs can be used to develop off-the-shelf preventive/therapeutic vaccine formulations.
Concetta Ragone, Angela Mauriello, Beatrice Cavalluzzo et al.· Journal of Translational Med...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.